Capacity Bio

mitophagy, mitochondrial modulators, small molecules

clearingsmall molecule

capacitybio.com·United States·Seed·$35M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-TYRO

Projects

First-in-Class Mitophagy Agonist Program

preclinical

drug program · medium · Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Advance a therapeutic mitophagy agonist intended to stimulate mitochondrial turnover for disease treatment applications.

Mitophagy agonist drug program based on mitochondrial turnover modulation; supplied evidence links the program to agents that stimulate mitochondrial turnover, but does not disclose a specific molecule or indication.

Described as being advanced in Capacity Bio's seed-stage pipeline following the 2023 financing.

Mitophagy Modulator Platform

preclinical

platform · high · Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop therapies that enhance identification and clearance of dysfunctional mitochondria by modulating mitophagy and mitochondrial biology.

Proprietary approach using small molecules, peptides, and nanoparticles to activate mitophagy pathways and promote clearance through autophagosomes and lysosomes.

Capacity Bio announced a $35 million seed financing on 2023-03-31 to advance novel mitophagy modulators and preclinical mitochondrial modulator programs.

Preclinical Mitochondrial Modulator Programs

preclinical

research program · medium · Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Discover and develop new mitochondrial modulators for therapeutic applications beyond the disclosed first-in-class mitophagy agonist.

Preclinical research programs focused on mitochondrial modulation using Capacity Bio's mitophagy and mitochondrial biology approach.

Identified as preclinical programs being advanced by Capacity Bio after the 2023 seed financing.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence